A new series of nitric oxide-donating fluoroquinolone/oximes was prepared in this study. The nitric oxide release from the prepared compounds was measured using a modified Griess colorimetric method. The antitubercular evaluation of the synthesized compounds indicated that ketone derivatives 2b and 2e and oximes 3b and 3d exhibited somewhat higher activity than their respective parent fluoroquinolones. Mycobacterial DNA cleavage studies and molecular modeling of Mycobacterium tuberculosis DNA gyrase were pursued to explain the observed bioactivity. More important, antibacterial evaluation showed that oximes 3c-e are highly potent against Klebsiella pneumoniae, with minimum inhibitory concentration (MIC) values of 0.06, 0.08, and 0.034 µM, respectively, whereas ketone 2c and oxime 4c are more active against Staphylococcus aureus than ciprofloxacin (MIC values: 0.7, 0.38, and 1.6 µM, respectively). Notably, the antipseudomonal activities of compounds 2a and 4c were much higher than those of their respective parent fluoroquinolones.

Download full-text PDF

Source
http://dx.doi.org/10.1002/ardp.202000180DOI Listing

Publication Analysis

Top Keywords

nitric oxide-donating
8
respective parent
8
parent fluoroquinolones
8
mic values
8
synthesis antimicrobial
4
antimicrobial evaluation
4
evaluation nitric
4
oxide-donating fluoroquinolone/oxime
4
fluoroquinolone/oxime hybrids
4
hybrids series
4

Similar Publications

A phase 3 adaptive dose selection trial of NCX 470, a nitric oxide-donating bimatoprost for open-angle glaucoma or ocular hypertension: The MONT BLANC study.

Contemp Clin Trials

December 2024

Author Employee of Nicox Ophthalmics, Nicox Ophthalmics, Inc. 4819 Emperor Blvd. Suite 400 Durham, NC 27703, United States.

Purpose: To identify the optimal dose of NCX 470, a nitric oxide (NO)-donating bimatoprost, for comparison to latanoprost in a phase 3 trial for open-angle glaucoma (OAG) or ocular hypertension (OHTN) using an adaptive dose selection design.

Patients And Methods: In this prospective, multicenter trial, subjects were randomized 1:1:1 to NCX 470 0.065 %, NCX 470 0.

View Article and Find Full Text PDF
Article Synopsis
  • Recent research shows that nitric oxide (NO) can trigger immunogenic cell death (ICD) in tumor cells by causing stress in the endoplasmic reticulum (ER) and destabilizing the mitochondrial membrane.
  • Because NO is unstable, the study introduces a new delivery method using a cell-penetrating polypeptide called poly(l-guanidine) (PLG), which can generate NO inside cells.
  • The helical structure of PLG not only penetrates cells but also creates reactive oxygen species (ROS) that lead to the production of NO, effectively inducing ICD through combined mechanisms involving ER stress and mitochondrial disruption.
View Article and Find Full Text PDF

We describe here the design and antitumor evaluation of benzofuroxan-based nitric oxide (NO)-donor hybrid derivatives targeting human carbonic anhydrases (hCAs) IX and XII. The most effective compounds, and , demonstrated potent dual action, exhibiting low nanomolar inhibition constants against hCA IX and significant NO release. Notably, compound showed significant antiproliferative effects against various cancer cell lines, particularly renal carcinoma A-498 cells.

View Article and Find Full Text PDF

IQ-1 (11-indeno[1,2-]quinoxalin-11-one oxime) is a specific c-Jun N-terminal kinase (JNK) inhibitor with anticancer and neuro- and cardioprotective properties. Because aryloxime derivatives undergo cytochrome P450-catalyzed oxidation to nitric oxide (NO) and ketones in liver microsomes, NO formation may be an additional mechanism of IQ-1 pharmacological action. In the present study, electron paramagnetic resonance (EPR) of the Fe complex with diethyldithiocarbamate (DETC) as a spin trap and hemoglobin (Hb) was used to detect NO formation from IQ-1 in the liver and blood of rats, respectively, after IQ-1 intraperitoneal administration (50 mg/kg).

View Article and Find Full Text PDF

Purpose: We evaluated the IOP-lowering efficacy and safety of latanoprostene bunod (LBN) ophthalmic solution 0.024% (Vyzulta®), the first topical nitric oxide-donating prostaglandin analog (PGA), in clinical practice.

Materials And Methods: A retrospective medical chart review from July 2021 to July 2023 of patients with open-angle glaucoma receiving LBN with at least 1 year follow-up was conducted.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!